Evidence map›Paper›PMID 36450472›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.

Takushi Manabe, Tomoko Tadokoro, Mai Nakahara, Kyoko Ohura, Koji Fujita, Joji Tani, Asahiro Morishita, Chikara Ogawa, Tsutomu Masaki

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Takushi ManabeDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Tomoko TadokoroDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Mai NakaharaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Kyoko OhuraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Koji FujitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Joji TaniDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Chikara OgawaDepartment of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Japan.
Tsutomu MasakiDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Kagawa University · JPTakamatsu Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A patient with genotype 1b chronic hepatitis C virus who had been treated with pegylated interferon and ribavirin (RBV) was treated with glecaprevir/pibrentasvir (GLE/PIB) for 12 weeks. A sustained virological response at post-treatment week 12 (SVR12) was achieved, but relapse occurred approximately 31 weeks after the end of treatment. The patient had a history of allergy to RBV and was treated with ledipasvir/sofosbuvir (LDV/SOF), achieving SVR12 and remaining hepatitis C virus-negative until 24 weeks after the completion of treatment. LDV/SOF can thus be a secondary treatment for GLE/PIB.

Indexed as

Hepatitis CHepatitis C, ChronicAminoisobutyric AcidsAntiviral AgentsBenzimidazolesCyclopropanesDrug Therapy, CombinationFluorenesGenotypeHepacivirusHumansLactams, MacrocyclicLeucineNeoplasm Recurrence, LocalProlinePyrrolidinesAminoisobutyric AcidsAntiviral AgentsBenzimidazolesCyclopropanesFluorenesglecaprevirLactams, Macrocyclicledipasvirledipasvir, sofosbuvir drug combinationLeucinepibrentasvirProlinePyrrolidinesQuinoxalinesRibavirinSofosbuvirSulfonamidesdirect-acting antiviralsglecaprevir and pibrentasvirhepatitis C virusledipasvir and sofosbuvirrelapse

Identifiers

PMID36450472
PMCPMC10518557
OpenAlexW4310565206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.